Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma

Alessandra Romano; Marco Santoro; Concetta Conticello; Sergio Siragusa; Francesco DI Raimondo; Giovanni Martinelli; Claudio Cerchione

doi:10.23736/S0031-0808.20.04141-5

Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma

Alessandra Romano, Marco Santoro, Concetta Conticello, Sergio Siragusa, Francesco DI Raimondo, Giovanni Martinelli, Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.

Original language	English
Pages (from-to)	13-20
Number of pages	8
Journal	Panminerva Medica
Volume	63
Issue number	1
DOIs	https://doi.org/10.23736/S0031-0808.20.04141-5
Publication status	Published - Mar 2021

Access to Document

10.23736/S0031-0808.20.04141-5

Fingerprint Dive into the research topics of 'Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma'. Together they form a unique fingerprint.

Cite this

Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. / Romano, Alessandra; Santoro, Marco; Conticello, Concetta; Siragusa, Sergio; DI Raimondo, Francesco; Martinelli, Giovanni ; Cerchione, Claudio.

In: Panminerva Medica, Vol. 63, No. 1, 03.2021, p. 13-20.

Research output: Contribution to journal › Article › peer-review

@article{aaf0e74d503b45248f80dafbd6c986c5,

title = "Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma",

abstract = "Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.",

author = "Alessandra Romano and Marco Santoro and Concetta Conticello and Sergio Siragusa and {DI Raimondo}, Francesco and Giovanni Martinelli and Claudio Cerchione",

year = "2021",

month = mar,

doi = "10.23736/S0031-0808.20.04141-5",

language = "English",

volume = "63",

pages = "13--20",

journal = "Panminerva Medica",

issn = "0031-0808",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "1",

}

TY - JOUR

T1 - Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma

AU - Romano, Alessandra

AU - Santoro, Marco

AU - Conticello, Concetta

AU - Siragusa, Sergio

AU - DI Raimondo, Francesco

AU - Martinelli, Giovanni

AU - Cerchione, Claudio

PY - 2021/3

Y1 - 2021/3

N2 - Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.

AB - Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy.

U2 - 10.23736/S0031-0808.20.04141-5

DO - 10.23736/S0031-0808.20.04141-5

M3 - Article

C2 - 32955184

VL - 63

SP - 13

EP - 20

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 1

ER -